Clinical trials: Cachexia; Cancer
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387282
- Testing
- Anamorelin HCl
- Where
- 46 sites in United States, Australia and 5 more
- Volunteers
- 495 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Cancer Cachexia, Atypical Anorexia Nervosa
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve quality of life (QoL) as far as possible.
- Trial name
- NCT02359123
- Testing
- Cannabics capsules
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Cannabics Pharmaceuticals Inc.
Muscle Wasting, Non Small Cell Lung Cancer
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
- Trial name
- NCT01355484
- Testing
- GTx-024
- Where
- 27 sites in United States
- Volunteers
- 321 people
- Sponsor
- GTx
Cachexia, NSCLC
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia
SF-C002 is a pilot study in patients with newly diagnosed NSCLC suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of…
- Trial name
- NCT02515032
- Testing
- Nutrifriend Cachexia
- Where
- 14 sites in Croatia, Italy and 2 more
- Volunteers
- 56 people
- Sponsor
- Smartfish AS
Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
An expanded access program (EAP) allows doctors to give medicine to seriously ill patients before it is approved by local regulatory agencies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma, Metastatic PDAC
- Trial name
- NCT07399015
- Testing
- mifomelatide
- Sponsor
- Endevica Bio
Cancer-associated Cachexia
Visugromab in Cachexia International Trial
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia.
- Trial name
- VINCIT (NCT07112196)
- Testing
- Visugromab (CTL-002)
- Where
- 74 sites in United States, Bulgaria and 10 more
- Volunteers
- 518 people
- Sponsor
- CatalYm GmbH
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
- Conditions
- Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia
- Trial name
- NCT07072728
- Testing
- Psilocybin therapy
- Where
- 3 sites in Australia
- Volunteers
- 87 people
- Sponsor
- Psyence Australia Pty Ltd
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Cachexia, Cancer
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients
To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and…
- Trial name
- NCT00851448
- Testing
- oral nutritional supplement, food for special medical purposes
- Where
- 3 sites in Italy, Poland
- Volunteers
- 17 people
- Sponsor
- Fresenius Kabi
Cancer Cachexia
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite.
- Trial name
- NCT00219817
- Testing
- RC-1291 HCl
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Cachexia, Digestive System Cancer
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
- Conditions
- Cachexia, Digestive System Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06940102
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, TKI-Based Therapy
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Cancer Weight Loss
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients.
- Trial name
- NCT06937177
- Testing
- TCMCB07
- Where
- 26 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Endevica Bio
Cancer Cachexia
Exploratory Trial of SAT-003 in Cancer Cachexia Patients With Discontinued Chemotherapy
This clinical trial aims to evaluate the feasibility of 'SAT-003' as well as its exploratory safety and efficacy in patients with cancer cachexia who have been diagnosed with solid tumors and have discontinued anticancer…
- Trial name
- NCT06476197
- Testing
- SAT-003
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- S-Alpha Therapeutics, Inc.
Cannabis Use, Cachexia; Cancer
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
A large number of patients with advanced cancer also suffer from cachexia. Cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and…
- Conditions
- Cannabis Use, Cachexia; Cancer, Advanced Cancer
- Trial name
- SERENITY (NCT04001010)
- Testing
- PPP011
- Where
- Canada
- Volunteers
- 334 people
- Sponsor
- Tetra Bio-Pharma
NSCLC, Fatigue
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).
- Conditions
- NSCLC, Fatigue, Cachexia
- Trial name
- NCT00866970
- Testing
- ALD518, Infusion of 0.9% Saline without ALD518
- Where
- 43 sites in Australia, Canada and 7 more
- Volunteers
- 124 people
- Sponsor
- CSL Behring
Anorexia, Cachexia
Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.
- Conditions
- Anorexia, Cachexia, Weight Loss
- Trial name
- NCT00637806
- Testing
- Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Par Pharmaceutical, Inc.
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Cancer Cachexia
An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia
This is an open-label, multicenter, multiple-dose Phase I/IIa clinical study to assess the safety/tolerability, PK characteristics,immunogenicity, and preliminary efficacy of INB301 Injection in patients with cancer cachexia.
- Trial name
- NCT07584057
- Testing
- INB301 Injection
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Yunnan Baiyao Group Co., Ltd.
Anorexia, Cachexia
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Betamarc is effective in improving the appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.
- Conditions
- Anorexia, Cachexia, Weight Loss, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00535015
- Testing
- Betamarc
- Where
- 6 sites in China, Taiwan
- Volunteers
- 70 people
- Sponsor
- Anaborex